Immunomedics Inc., of Morris Plains, N.J., engaged Greenhill & Co. Inc. to serve as a strategic advisor primarily to assist in its ongoing efforts to out-license sacituzumab govitecan (IMMU-132), the company's lead investigational antibody-drug conjugate. (See BioWorld Today, June 6, 2016.)